Active Ingredient History

  • Now
Prexasertib (LY2606368) is a small molecule checkpoint kinase inhibitor, mainly active against CHEK1, with minor activity against CHEK2. This causes induction of DNA double-strand breaks resulting in apoptosis. It was developed by Eli Lilly but the company announced in 2019 it was dropping prexasertib from active development, although clinical trials continue. Research continues into the efficacy of prexasertib in treatment of acute myeloid leukemia, myelodysplastic syndrome, rhabdomyosarcoma, and medulloblastoma.   Wikipedia

  • SMILES: COc1cccc(OCCCN)c1c2cc(Nc3cnc(cn3)C#N)n[nH]2
  • Mol. Mass: 365.4
  • ALogP: 2.22
  • ChEMBL Molecules:
More Chemistry
ly2606368 | ly-2606368 | prexasertib


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue